Background Depression and chronic pain are two major chronic non-communicable
diseases (CNCD). Considering the bidirectional relationship between obesity and CNCD, it …

Background: Topiramate, a novel anticonvulsant, has shown promise in preliminary open
trials in bipolar disorder, but there are no studies in primary depression. Topiramate's …

BACKGROUND: Weight gain is a common adverse effect of many psychotropic medications
including antipsychotics, antidepressants, and mood stabilizers. There is a growing body of …

Obesity has emerged as a widespread disease with epidemic proportions, necessitating
effective management to enhance the overall health outcomes of patients. Medical …

Objective: This study aims to see whether patients in a real-world setting taking topiramate
for varied indications experience significant weight loss. Methods: This was a retrospective …

Background The weight-gain caused by many psychotropic drugs is a major cause for poor
compliance with such medications and could also increase cardio-vascular morbidity among …

Aims To conduct a systematic review with meta-analysis to determine the efficacy and safety
of topiramate as monotherapy for weight reduction in patients with type 2 diabetes mellitus …

OBJECTIVE To review the evidence of weight loss with use of topiramate in patients with
mood disorders. DATA SOURCES Literature search included MEDLINE (1966—December …

Topiramate was associated with weight loss in clinical trials. We summarize the evidence on
the efficacy and safety of topiramate in the treatment of overweight/obesity. The databases …

Background Overweight/obesity and depression are highly co-occurring conditions with
shared pathophysiology as well as social and economic determinants. To our knowledge …